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1. Experimental procedures
Materials and Methods.
Unless otherwise stated, common chemicals and solvents (HPLC grade or reagent grade quality) were purchased from commercial sources and used without further purification.
Peptide grade DMF was purchased from Scharlau. Fmoc-protected amino acids, resins and coupling reagents for solid phase synthesis were obtained from Novabiochem, Bachem or Iris
Biotech. Copper(I) catalyst (Cu nanopowder, CAS 7440-50-8) was purchased from Alfa
Aesar. Milli-Q water was directly obtained from a Milli-Q system equipped with a 5000-Da ultrafiltration cartridge. Fluorescein-5(6)-carboxamidocaproic acid N-succinimidyl ester was purchased from Aldrich. All the assayed compounds displayed a purity ≥95%, determined by HPLC analysis.
Analytical reversed-phase HPLC analyses were carried out on a Jupiter Proteo column (250x4.6 mm, 4 µm, flow rate: 1 mL/min), using linear gradients of 0.045% TFA in H 2 O (solvent A) and 0.036% TFA in ACN (solvent B). In some cases, small-scale purification was carried out using the same column. Large-scale purification was carried out on a Jupiter
Proteo semipreparative column (250 x 10 mm, 10 µm, flow rate: 3 mL/min), using linear gradients of 0.1% TFA in H 2 O (solvent A) and 0.1% TFA in ACN (solvent B). After several runs, pure fractions were combined and lyophilized.
NMR spectra were recorded at 25 ºC on Varian Mercury 400 MHz spectrometers using deuterated solvents. Tetramethylsilane (TMS) was used as an internal reference (δ 0 ppm) for 1 H spectra recorded in CDCl 3 and the residual signal of the solvent (δ 77.16 ppm) for 13 C spectra. For CD 3 OD, acetone-d 6 , DMSO-d 6 or D 2 O, the residual signal of the solvent was used as a reference.
High resolution MALDI-TOF mass spectra were recorded on a 4800 Plus MALDI-TOF/TOF spectrometer (Applied Biosystems) in the positive-ion mode using 2,4-dihidroxybenzoic acid as a matrix. ESI mass spectra (ESI-MS) were recorded on a Micromass ZQ instrument with S4 single quadrupole detector coupled to an HPLC. High resolution electrospray mass spectra (HR ESI MS) were obtained on an Agilent 1100 LC/MS-TOF instrument.
Cell lines.
The SK-MEL-28 human melanoma and CAPAN-1 pancreas adenocarcinoma cell lines were from the American Tissue Culture Collection (ATCC, Rockville, MD, USA). The 1BR3G human skin fibroblasts were from the European Collection of Cell Cultures (ECACC, Porton, UK). Cells were maintained in Dulbecco's Modified Eagle Medium (DMEM) supplemented with 10% FBS (Gibco-BRL, Grand Island, NY, USA) and 100 U mL -1 penicillinstreptomycin (Gibco-BRL) at 37˚C in a humidified atmosphere containing 5% CO 2 . Cell growth and morphology were assessed using an inverted microscope.
Synthesis of cis,cis,trans-[PtCl 2 (2-methylpyridine)(NH 3 )(OH) 2 ] (3).
To a solution of picoplatin (100 mg, 0.26 mmol) in a 1:10 mixture of water and heptane (20 mL), hydrogen peroxide (15 mol equiv.) was added dropwise and the mixture was stirred at 80ºC for 2 h. Once at room temperature, the reaction mixture was cooled with an ice bath for 1 h. Cyclization was carried out in DMF (ca 1 mL/ mg crude peptide) at pH 8-9 (adjusted with DIPEA) by using PyBOP (1 mol equiv.). After it was stirred for 18 h at room temperature, the reaction mixture was evaporated in vacuo. Diethyl ether was used to precipitate the peptides 7
and 9, which were used in the next step without further purification. 
RAFT-{c(RGDfK)} 4 (11).
The Boc-protected RAFT cyclodecapeptide scaffold 9, c[- 
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-Picoplatin(IV)-RAFT-{c(RGDfK)} 4 conjugate (6).
To a solution of 4 (0.68 mg, 1.6 mol equiv.) and HATU (0.48 mg, 1.5 mol equiv.) in anhydrous DMF (0.3 mL), DIPEA (0.7 µL, 4.5 mol equiv.) was added. After stirring for 2 min at room temperature, the reaction mixture was added to RAFT peptide 11 (3.8 mg, 0.82 µmol) previously dissolved in anhydrous DMF (0.1 mL) and DIPEA (1.4 µL, 10 mol equiv.). After stirring for 2 h at room temperature, the solvent was evaporated in vacuo and the conjugate was purified by semipreparative HPLC (gradient from 0 to 70% B in 30 min, flow rate: 3 mL/min, R t = 20.0 min). Overall yield S9 (synthesis + purification): 1.1 mg of a white solid, 27%. Characterization: R t = 14. 
Integrin expression analysis.
The expression of α V β 3 and α V β 5 integrins on the cell surface was analyzed by double immuno-fluorescence. The cells were incubated for 30 min at 4˚C with monoclonal antibodies against human α V β 3 (clone LM609) (Millipore, Temecula, CA) and α V β 5 integrin (sc-81632) (Santa Cruz Biotechnology, Santa Cruz, CA, USA) or medium alone as negative control.
After washing with phosphate-buffered saline (PBS) (Gibco-BRL), cells were incubated for additional 30 min at 4˚C with the Alexa-Fluor 488-conjugated goat anti-mouse IgG antibody (Invitrogen, Carlsbad, CA, USA). Next, the cell fluorescence was analyzed using a 
Internalization experiments with 12 and 13.
The uptake efficiency of 12 and 13 by the cells was quantified by flow cytometry. 60.000 cells were seeded onto 24-well plates and allowed to attach for 24 h. Then, the cells were treated with either 12 or 13 at 25 µM, or medium alone as a control, for 1 h at 37ºC. After and cisplatin (Sigma-Aldrich, St. Louis, MO) were dissolved in DMSO to provide a 10 mM solution, which was then diluted in Milli-Q to obtain a 1 mM stock solution. Appropriate aliquots of these solutions were diluted in the cell culture medium to obtain the final working solutions. Aliquots of 5000 CAPAN-1, 4000 SK-MEL-28 and 5000 1BR3G cells were seeded on 96-well plates 24 h prior to the treatments. Then, cells were treated for 72 h with the corresponding compound at concentrations ranging from 0 to 50 µM. After removal of the treatment, cells were washed with PBS and incubated for additional 2 h in the darkness with fresh culture medium (100 µL) with MTT (10 µL). The medium was discarded and DMSO (100 µL) was added to each well to dissolve the purple formazan crystals. Plates were agitated at room temperature for 2 min and the absorbance of each well was determined with an absorbance microplate reader (ELx800, BioTek, Winooski, USA) at a wavelength of 570 nm.
Three replicates for each compound were used, and all treatments were tested at least in three independent experiments. For each treatment, the cell viability was determined as a percentage of the control untreated cells, by dividing the mean absorbance of each treatment by the mean absorbance of the untreated cells. The concentration that reduces by 50% the cell viability (IC 50 ) was established for each compound using a four-parameter curve fit (Gen5 Data Analysis Software, BioTeck).
Platinum accumulation in cancer cells.
For platinum cellular uptake studies, 1.5 x10 6 SK-MEL-28 and CAPAN-1 cells were plated in 100 mm Petri dishes and allowed to attach for 24 h. Next, the plates were exposed to picoplatin or to conjugates 5 or 6 at a concentration (0.5 µM) below their corresponding IC 50
values. Additional plates were incubated with medium alone as negative control. After 24 h of S11 incubation, the cells were rinsed three times with cold PBS and harvested by trypsinization.
The number of cells in each sample was counted manually in a haemocytometer using the trypan blue dye exclusion test. Then the cells were centrifuged to obtain the whole cell pellet for ICP-MS analysis. All experiments were conducted in triplicate.
ICP-MS analysis.
The whole cell pellets were dissolved in 400 µL of concentrated 60 % v/v nitric acid, and the samples were then transferred into wheaton v-vials (Sigma-Aldrich) and heated in an oven at 373 K for 18 h. The vials were then allowed to cool, and each cellular sample solution was transferred into a volumetric tube and combined with washings with Milli-Q water (1.6 mL).
Digested samples were diluted 10 times with Milli-Q to obtain a final HNO 3 concentration of approximately 1.2% v/v. Platinum content was analyzed on an ICP-MS Perkin Elmer Elan 6000 series machine at the Centres Científics i Tecnològics of the Universitat de Barcelona.
The solvent used for all ICP-MS experiments was Milli-Q water with 1% HNO 3 . The platinum standard (High-Purity Standards, 1000 µg/mL + 5 µg/mL in 5% HNO 3 ) was diluted with 1% HNO 3 to 20 ppb. Platinum standards were freshly prepared in Milli-Q water with 1% HNO 3 before each experiment. The concentrations used for the calibration curve were in all cases 0, 0.2, 0.4, 1, and 2 ppb. The isotope detected was 196 Pt and readings were made in triplicate. Rhodium was added as an internal standard at a concentration of 10 ppb in all samples.
Statistical analysis.
The statistical analysis was performed with the SPSS statistical software for Windows 
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Figure S-2 Reversed-phase HPLC traces for peptide 12: reaction crude (left) and purified (right).
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Characterization of Pt(IV)-peptide conjugates (5 and 6).
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